RxDoctor Payments Data

Enawgaw Mehari, MD

Neurology · Dickson, TNNPI 1386608149

Payments from drug & device makers

$7,750in general payments, 2019–2025

Across 456 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$687
  • Pfizer$653
  • Lilly USA, LLC$548
  • Lundbeck LLC$507
  • Amgen$447
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$7,68699%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,750 in reported general payments places this provider in the 60th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$187,896
Medicare patients
354
Services billed
3,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant314$363,318
Nurtec OdtRimegepant Sulfate176$228,061
UbrelvyUbrogepant163$179,061
IngrezzaValbenazine Tosylate14$114,241
Emgality PenGalcanezumab-Gnlm63$49,791
Aimovig AutoinjectorErenumab-Aooe35$41,465
OngentysOpicapone17$22,668
VyeptiEptinezumab-Jjmr11$19,915
BotoxOnabotulinumtoxina12$17,533
NamzaricMemantine Hcl/Donepezil Hcl13$10,447
Oxcarbazepine285$8,581
Entacapone44$5,863
Carbidopa-LevodopaCarbidopa/Levodopa315$4,831
Gabapentin488$4,474
Levetiracetam227$4,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox, Namzaric$1,167$570,359502 claims
PfizerNurtec Odt$653$228,061176 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$687$136,90831 claims
Lundbeck LLCVyepti$507$19,91511 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$156$4,09462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 361 neurology providers in Tennessee.

Other neurology in Dickson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →